What is BOLD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BOLD?

P/E (TTM) is n/a and 52-week range is $0.96 to $3.16 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BOLD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BOLD?

The company profile lists net income (TTM) near $-64M, EPS (TTM) near $-2.86 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Boundless Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 22.5M shares outstanding, ISIN US10170A1007 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Boundless Bio Inc

$BOLD

Health Care · Biotechnology

Run Scenarios

$2.53

-1.94%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

Employees

Website

boundlessbio.com/

IPO

2024-03-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)